
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. continues to exhibit strong growth potential driven by its leading product, cabozantinib, which has established itself as a key treatment in renal cell carcinoma (RCC) and has expanded into neuroendocrine tumors (NETs) following recent label approvals based on promising study outcomes. The positive momentum surrounding zanzalintinib, particularly its favorable overall survival data in the metastatic colorectal cancer population, further underscores Exelixis's capacity for innovation and market expansion. Ongoing clinical trial successes and the potential for new indications signal a sustainable growth trajectory, reinforcing confidence in Exelixis's long-term financial prospects.
Bears say
Exelixis Inc. faces a significant revenue decline projected at 80% by 2032 due to the impending patent cliff in 2031, which is substantially greater than the Street's estimate of 68%. The company encounters multiple competitive risks, including potential market share erosion for its key product, cabozantinib (Cabo), and uncertainty regarding the successful launch in new indications such as HCC. Additionally, developmental risks concerning zanzalintinib and the likelihood of delays or failures in regulatory approvals further contribute to a cautious outlook on the company’s financial stability.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares